SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Lipocine Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit – LPCN


STEVENSON, Md., July 28, 2016 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Lipocine Inc. (Nasdaq:LPCN) (“Lipocine” or the “Company”) securities during the period between June 30, 2015 and June 28, 2016, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until August 30, 2016 to seek appointment as lead plaintiff.

If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Lipocine securities during the Class Period.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that the Company’s filing of its New Drug Application for LPCN 1021, an oral testosterone replacement therapy, to the U.S. Food and Drug Administration (“FDA”) contained deficiencies.

According to the complaint, following a June 29, 2016 press release announcing the Company’s receipt of a Complete Response Letter for LPCN 1021 from the FDA, which identified deficiencies related to the dosing algorithm for the label, the value of Lipocine shares declined significantly.

If you have suffered a loss from investment in Lipocine securities purchased on or after June 30, 2015 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at hoffman@browerpiven.com or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.


            

Contact Data